GemVax & KAEL said its study results of GV1001 showing an inhibitory effect on prostate cancer cell metastasis was published in the international journal, Cell & Bioscience.

The company research team found the possibility that its Alzheimer’s drug candidate GV1001 could be a GnRHR ligand that inhibits the metastasis through the Gas/cAMP pathway in experiments conducted with prostate cancer cells.

Researchers pointed out that the study results provide the base for GV1001 to have a preventive effect against the metastasis of prostate cancer.

GemVax & KAEL officials have confirmed the therapeutic effect of GV1001 on cancers of the urogenital system, such as prostate cancer and kidney cancer, through several papers.

“Several other studies also showed a therapeutic effect of GV1001 on cancers of the urogenital system, such as prostate and kidney cancers,” a GemVax & KAEL official said. “The recent paper proved GV1001 inhibitㄴ the metastasis of prostate cancer.”

The official added that the company would positively consider developing a therapy for urogenital cancers with additional studies on the mechanism of GV1001.

The research team, led by Seoul National University College of Medicine Professor Kang Keon-wook, conducted the study, titled, Anti-metastatic effect of GV1001 on prostate cancer cells; roles of GnRHR-mediated Gαs-cAMP pathway and AR-YAP1 axis.

According to the 2018 report of the National Cancer Registry Program, prostate cancer was the seventh most common cancer and fourth among men. In addition, one-third of all prostate cancers metastasize, and 65 to 75 percent of them spread to the bone.